Numis Securities Ltd reaffirmed their buy rating on shares of Horizon Discovery Group PLC (LON:HZD) in a research report released on Wednesday morning. Numis Securities Ltd currently has a GBX 260 ($3.22) target price on the stock.

HZD has been the topic of several other research reports. Panmure Gordon reaffirmed a buy rating and set a GBX 205 ($2.54) price target on shares of Horizon Discovery Group PLC in a research report on Wednesday, November 9th. Beaufort Securities reaffirmed a speculative buy rating on shares of Horizon Discovery Group PLC in a research report on Wednesday, September 21st. Finally, N+1 Singer reaffirmed a buy rating and set a GBX 194 ($2.40) price target on shares of Horizon Discovery Group PLC in a research report on Tuesday, September 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of Buy and an average price target of GBX 217.25 ($2.69).

Shares of Horizon Discovery Group PLC (LON:HZD) opened at 128.75 on Wednesday. Horizon Discovery Group PLC has a 52-week low of GBX 125.00 and a 52-week high of GBX 188.06. The firm’s market cap is GBX 121.18 million. The stock has a 50 day moving average price of GBX 139.31 and a 200-day moving average price of GBX 155.62.

About Horizon Discovery Group PLC

Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Stock Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related stocks with our FREE daily email newsletter.